BMO Capital Maintains Outperform on Ingevity, Raises Price Target to $62
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
BMO Capital analyst John McNulty maintains Ingevity (NYSE:NGVT) with a Outperform and raises the price target from $56 to $62.
BMO Capital analyst John McNulty maintains Ingevity (NYSE:NGVT) with a Outperform and raises the price target from $56 to $62.